[Current status of treatment for chronic renal insufficiency in Morocco].
In 1980, the first Moroccan hemodialysis center was founded in Casablanca. The number of centers has been increasing since then, to reach 61 centers to wards the of 1996. There are 1800 hemodialysed (males 59%, females 41%) with and average age of 51 +/- 4 years. In about one third of the cases, the cause of the end stage renal failure remains unknown. However, chronic glomerulonephritis comes at the head of known causes (25%), followed by interstitial nephritis (19%). A temporary vascular access (catheter) was necessary in 81% of cases when dialysis has started in emergency in 61% of patients. Infections were the most frequent complications (21%) namely septicaemia (8%) and tuberculosis (7%). The vaccination against hepatitis B virus is done systematically in all the centers, and the number of chronic carriers of HBS Ag is about 7%. Further more, serological C virus is positive in 40% of the hemodialysed patients. Cardio-vascular complications were dominated by percarditis (13%) especially at the beginning of the dialysis. Anaemia remains very frequent and often very important requiring multiple blood transfusions (35%) in the absence of erythropoietin treatment. The death rate, which is very difficult to estimate, is of about 18%. Peritoneal dialysis was used in 50 patients but only four patient continued on peritoneal dialysis therapy. 108 patients were transplanted (23 cases in Morocco, 85 in other countries) with a waiting list of 0 to 12 years. Hemodialysed Moroccan's population is characterised by the high number of unknown causes and the gravity of the admission stage. A renal effort in prophylactic should be performed to avoid certain causes of renal failure.
Bourquia
A
A
AL AMAL, Centre de néphrologie-dialyse, Casablanca.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000554:Ambulatory Care Facilities / Q000706:statistics & numerical data; D000740:Anemia / Q000209:etiology / Q000628:therapy; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology; D002353:Carrier State; D002408:Catheters, Indwelling / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D015897:Comorbidity; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D005921:Glomerulonephritis / Q000150:complications / Q000453:epidemiology; D006525:Hepatitis, Viral, Human / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D007223:Infant; D007239:Infections / Q000453:epidemiology; D007676:Kidney Failure, Chronic / Q000150:complications / Q000453:epidemiology / Q000628:therapy*; D016030:Kidney Transplantation / Q000706:statistics & numerical data*; D008297:Male; D008875:Middle Aged; D009018:Morocco / Q000453:epidemiology; D009395:Nephritis, Interstitial / Q000150:complications / Q000453:epidemiology; D010530:Peritoneal Dialysis / Q000706:statistics & numerical data; D006435:Renal Dialysis / Q000009:adverse effects / Q000706:statistics & numerical data*; D065227:Transfusion Reaction; D014611:Vaccination
D004921:Erythropoietin